<SEC-DOCUMENT>0000950170-22-026104.txt : 20221206
<SEC-HEADER>0000950170-22-026104.hdr.sgml : 20221206
<ACCEPTANCE-DATETIME>20221206173023
ACCESSION NUMBER:		0000950170-22-026104
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221206
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221206
DATE AS OF CHANGE:		20221206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40629
		FILM NUMBER:		221448570

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cadl-20221206.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-12-06T16:59:24.5274+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cadl="http://www.candeltx.com/20221206" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_958d0a12-97a6-4447-9c3a-7faf73fcb3d7" name="dei:EntityCentralIndexKey" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d">0001841387</ix:nonNumeric><ix:nonNumeric id="F_e2f645b9-9d1f-40d2-bef2-0cd029d4b508" name="dei:AmendmentFlag" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cadl-20221206.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001841387</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4671403c-e29d-4e7e-8830-aba580030f46" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0e40acb-49bb-4f3a-8331-6c3f4d4812d1" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 6, 2022</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_20fc58f1-d309-49c4-8e36-1bf908e8002c" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CANDEL THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.343%;"></td>
    <td style="width:33.324%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f0edec0d-127c-4532-aa0e-9da257a9146b" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_25c5ac45-a99a-4271-846b-c9b1c4db0e9b" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40629</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f00976c1-9d79-41b7-8301-7f25230474da" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52-2214851</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d02ba6ea-9775-4cc5-a358-5bc8e17cb0f3" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117 Kendrick St</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">., </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2289bd33-7cbd-432d-bbb8-903846bea75f" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 450</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_345a3e49-08f3-4c73-9ba4-b59cee65b4f0" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Needham</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9c8aa16-c640-49e8-a6fb-bead3854c60e" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2627a87b-b897-4b64-aced-8b22dede3239" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">02494</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a4be6d04-c1e2-4f51-a4dd-8b7645f8f28a" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_86a2e8e9-c974-46f7-9f7d-a28da55ca648" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">916-5445</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_97a8b751-6b04-4de0-ae08-bce7027bbb9b" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_256d27b3-0155-43f2-8a64-93a2a314d2be" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e577c49d-2532-49df-9c88-b721c09184a7" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0de11d34-f3b5-41a9-bb7a-f93801704a7b" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ac4b101-e471-4761-8c6f-68fd8a1a4e77" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.01 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d655a468-7860-46e7-99b2-f7762fc22b55" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CADL</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0265dbfc-8808-4830-b6dc-395f49d43e22" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x2009;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x2009;240.12b-2 of this chapter).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d1c12c6-09b0-4b18-99eb-967006ca9738" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84e36f53-d742-4581-92d7-162a01a42729" contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 6, 2022, Candel Therapeutics, Inc. (the &#34;Company&#34;), hosted a virtual Research and Development (R&amp;D) Day. The event provided an extensive overview of the Company&#x2019;s viral immunotherapy approach and oncology-focused pipeline, with new data presented from its phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with stage III/IV non-small cell lung cancer, as well as an update on its phase 3 clinical trial of CAN-2409 in high-grade glioma.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A copy of the full press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.083%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:90.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;99.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><a href="cadl-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press Release dated December 6, 2022</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Candel Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: December 6, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Paul Peter Tak</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paul Peter Tak, M.D., Ph.D., FMedSci</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cadl-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img160460863_0.jpg" alt="img160460863_0.jpg" style="width:222px;height:98px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Candel Therapeutics R&amp;D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survival</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Highlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma (HGG) demonstrating a median overall survival (mOS) of 11.6 months</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Due to promising clinical activity, portfolio decision made to prioritize CAN-3110 in HGG and not to pursue phase 3 clinical trial of CAN-2409 in HGG</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provided scientific rationale of partnership with University of Pennsylvania, leveraging Candel&#x2019;s enLIGHTEN&#153; Discovery Platform to create novel viral immunotherapies to enhance CAR-T cell therapies in solid tumors </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Candel&#x2019;s Research Advisory Board Members Drs. James P. Allison, Roy Herbst, and Padmanee Sharma shared their perspectives on the promise of viral immunotherapy for solid tumors</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NEEDHAM, Mass., December 6, 2022 (GLOBE NEWSWIRE) -- </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Candel Therapeutics, Inc. (&#x201c;Candel&#x201d; or &#x201c;the Company&#x201d;) (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today held its Research and Development Day to provide an extensive overview of the Company&#x2019;s unique viral immunotherapy platforms and to review updated clinical data from its oncology-focused pipeline.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;We are proud to present data and a growing body of evidence from our clinical stage pipeline,&#x201d; said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. &#x201c;The totality of clinical data demonstrates that CAN-2409 and CAN-3110 are active investigational viral immunotherapies with robust biomarker evidence of local and systemic immune responses. We look forward to advancing our product candidates through the next phase of clinical development towards registration and beyond to bring important treatment options to patients in need.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Candel provided updates on a broad range of its programs. Highlights included:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 clinical trial of CAN-2409 in non-small cell lung cancer</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robust evidence of local and systemic anti-tumor activity in patients with inadequate response to immune checkpoint inhibitors </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disease control rate of 77 percent (20/26) in patients entering trial with disease progression (cohort 2)</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sustained and ongoing clinical responses greater than 1 year</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAN-2409 favorably changed the trajectory of tumor progression </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decreased tumor size of RECIST target lesions in most patients </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduced uninjected tumor size in 14/21 patients (67 percent)</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overall response rate of 13 percent (4/30) across cohorts 1 and 2</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Durable disease stabilization translating into encouraging preliminary evidence of progression-free survival</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consistent induction of local and systemic cytotoxic T cell response </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increased infiltration of CD8+ T cells in the tumor microenvironment</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Systemic expansion of effector T cells and increase in soluble granzyme B levels in peripheral blood </font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Favorable safety/tolerability profile </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Only two administrations with relatively simple procedure</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most treatment-related adverse events were grade 1/2</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Next clinical data update expected in 2H 2023</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 clinical trial of CAN-3110 in recurrent HGG</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treatment is well tolerated, with no dose limiting toxicity observed&#x200b;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.6 month mOS in recurrent HGG with a single dose &#x200b;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evidence of persistent herpes simplex virus (HSV)-1 antigen and HSV-1 replication consistent with mechanism of action&#x200b;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robust evidence of immune activation&#x200b;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now evaluating the effects of multiple doses of CAN-3110 supported by Break Through Cancer foundation</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 clinical trial of CAN-2409 in combination with nivolumab in HGG</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data suggest combination is well tolerated, with no dose-limiting toxicity and no added toxicity to standard of care (SoC)</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mOS in evaluable patients appeared comparable to historical SoC</font></div></div>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biomarker analysis indicates the ability to activate a systemic immune response with a single administration of CAN-2409 in patients with HGG</font></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reaffirmed guidance of phase 2 and 3 clinical trials of CAN-2409 in prostate cancer</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3 clinical trial in localized intermediate/high-risk prostate cancer expected to read out in Q4 2024 (event-driven endpoint)</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 clinical trial in active surveillance, localized prostate cancer expected to read out in Q4 2023 (event-driven endpoint)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enLIGHTEN Discovery Platform launched</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Novel discovery engine to generate viral immunotherapies by design </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discovery partnership with University of Pennsylvania to explore the effects of investigational viral immunotherapy in combination with CAR-T cells in solid tumor models</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data-driven, human-based, novel platform enabling future discovery partnerships </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate highlights</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diverse pipeline of viral immunotherapies with proof of concept in multiple difficult-to-treat solid tumors</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strong scientific support from high-profile Research Advisory Board&#x200b;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents of $77.2M as of September 30, 2022 with runway into Q1 2024&#x200b;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The recorded webcast is accessible under &#x201c;Events and Presentations&#x201d; on the Investors page of the Company&#x2019;s website at </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">https://ir.candeltx.com/news-and-events/events-and-presentations</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or by </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clicking here</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. A replay of the event will be available for up to a year.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">About Candel Therapeutics</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Candel is a clinical stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies. Candel&#x2019;s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two viral immunotherapy platforms based on novel, genetically modified adenovirus and HSV constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. Candel&#x2019;s enLIGHTEN&#153; Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For more information about Candel, visit: </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">www.candeltx.com</font></font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This press release includes certain disclosures that contain &#x201c;forward-looking statements,&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;would,&#x201d; &#x201c;should,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;target&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company&#x2019;s programs; the Company&#x2019;s ability to efficiently discover and develop product candidates; the Company&#x2019;s ability to obtain and maintain regulatory approval of product candidates; the Company&#x2019;s ability to maintain its intellectual property; the implementation of the Company&#x2019;s business model, and strategic plans for the Company&#x2019;s business and product candidates, and other risks identified in the Company&#x2019;s SEC filings, including the Company&#x2019;s Quarterly Report on Form 10-Q filed on November 10, 2022, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company&#x2019;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Media Contact</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cassidy McClain</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Account Director</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evoke Canale</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(237,125,49,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cassidy.McClain@evokegroup.com</font><font style="color:rgba(237,125,49,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(619) 694-6291</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investor Contact</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sylvia Wheeler</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Wheelhouse Life Science Advisors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(237,125,49,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">swheeler@wheelhouselsa.com</font><font style="color:rgba(237,125,49,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"></font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img160460863_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img160460863_0.jpg
M_]C_X  02D9)1@ ! 0  W #<  #_X0" 17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (  (=I  0    !    3@
M      #<     0   -P    !  .@ 0 #     0 !  "@ @ $     0   ?V@
M P $     0   .(     _^T .%!H;W1O<VAO<" S+C  .$))300$
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" C_W0 $ "#_V@ , P$
M A$#$0 _ /[\**** "BBB@ HHHH **** "BBB@"*8R"%FA W[3M!Z9[5\O\
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MPVDJE-Z57T;]/-RL[V8M%%%?M1^(A1110 4444 %%%% !1110 4444 %%%%
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M7]GOX00LFG:5&9+FZF),UY>2X,]S)VW2-S@< <"O"XMEETU"KA6N:6Z6UO\
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M.-O7?DJ_VNC_ (D<^+_A3]&?Y<26\+,$5%))P/E'4_A6O_PBNM9_Y!MWZ?\
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MQL20:)#@W3<'(\YBL0/<;J_I5U"_M-+L)]3OY$B@MHGGFED(5$2-2S,Q/
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MY_\ ^4IU_P#]B%X=_P#1<M?Z5@ZCZU_FI_\ !S]_RE.O_P#L0_#O_HN6ON.
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M#%?1\ _[E7]?T/,S_P#CTOZZG^T/X(_Y$G1_^P9:_P#HE*Z>N8\$?\B3H_\
MV#+7_P!$I73U^5UOCEZGUT?AB%?BA_P<.?\ *(WXK?\ 7#2__3C;U^U]?BA_
MP<.?\HC?BM_UPTO_ -.-O7;DO^]TO5&&*_AR]#_,W^!W_);/!W_8U:5_Z5QU
M_LZI]Q?]T?RK_&*^!W_);/!W_8U:5_Z5QU_LZI]Q?]T?RK[KQ'_BT/1G@<-?
M!4]1U!Z445^9'TQ\\?M3_LU_#+]KCX%>(?@+\6;%+W1]>L)+9U(^>"4KF*>)
MN=LD;X92!P17^1Y^U3\ O$/[+?[17C']GSQ26>Z\*ZY<:8)B,>? IW03=O\
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MC;&_P:ENS_(_S4/@3_R73P3_ -CCH?\ Z70U_LN>'O\ D V7_7I%_P"@"O\
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M_:;N[==JRF/.X0Q,0SOC ''4U_E9>,/%?BKXI>.M2\:>)9IM0UO7]4FU"\E
M+R7%W>2EVP.I+.V !]*_3/#_ "R:G/%S6B5D?,\1XI<JHK=G]9__  :._"Z\
MU/X\?$SXNR1M]ETSP]:Z1%+C@SW,I=ESZA!FO[RCR!]<U^(G_! _]A>__8F_
M89TJ/QA;&V\4^,Y1XGUV&1=LD'G*/L\#9YRD>,CU-?MV*^3XHQD<1C:DX[+3
M[CU\KH.G0C%BU^'7_!Q5_P HH_B'_P!=-+_]+X*_<6OPZ_X.*O\ E%'\0_\
M?TO_ -+X*X\C_P!]H?XH_FC7&_P:GH_R/\S+X:>'K#Q=\2_#GA+5-XM=5U_3
M=,N3&</Y-W<QPN5/8[6.#ZU_H,Z7_P &KO\ P3LOM-M[V74?'(:6".5@-2&
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MC36_VR/BY8?MFP?L]VGA5GT)[F*UDOS#-YS)+&':[60?N_*0G!&.QYS7T_\
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M<>:>.F.F?^!5^7?[7_\ P=C?#W3=)N?#_P"Q9X/OM2U"2,QQ^(/%ZK;VT)/
M=+2)F>0CJ-S@>HK^.R/]D#]K*2[_ +/B^&7C\S$[?+&@W^<_]^?ZU]J_ +_@
MB+_P4N_:$U2"TT#X::KH-I,RA]3\6%=+MXE;^(K)F8_\!C/X5ST^%<JH/VE2
MI=+NU8VGFV+J+EA"S]#Y2^)?[<_[5GQ8^/L?[3?C3QIK4WC&VOEO[#4HYVB%
MFR-N2.WC4A$C7H$ P1UK_3K_ ."2W[2?QY_:O_8A\*?&+]HWP_)H/B.]C>%S
M(AB_M&"'"Q7PB;YD$X^;;^(P#7Y"_P#!-_\ X-E_@C^SGJ]C\5OVNKRU\?\
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M359RHJ-1:K0D'4?6O\U/_@Y__P"4IU__ -B'X=_]%RU_I5].:_@R_P"#B/\
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MYDU<]S+L14JP<JD;,DHHI",U\Z=Q_$G_ ,'@)(N/@>1_?\28_P"^+&OY[O\
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M.TOPK*_PSL-'M1=>*3=VJQ*\6@7%FR" R^>7$[JG$>.<]*_6O_@JQ^PWI/\
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M** "BBB@ ]SV]:,8XZ\_YQ110 4HZTE% !TZ#&>N,=?UHHHH __4_OPHHHH
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cadl-20221206_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-12-06T16:59:24.2377+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cadl-20221206_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-12-06T16:59:24.1031+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cadl-20221206.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cadl-20221206.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-12-06T16:59:24.1532+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.candeltx.com/20221206" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cadl="http://www.candeltx.com/20221206" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cadl-20221206_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cadl-20221206_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139828918679328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001841387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  06,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CANDEL THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2214851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">916-5445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CADL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>cadl-20221206_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cadl-20221206.xsd" xlink:type="simple"/>
    <context id="C_07573f72-2713-49f5-bb06-7e7b8e980e8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001841387</identifier>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_958d0a12-97a6-4447-9c3a-7faf73fcb3d7">0001841387</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_e2f645b9-9d1f-40d2-bef2-0cd029d4b508">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_4671403c-e29d-4e7e-8830-aba580030f46">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_d0e40acb-49bb-4f3a-8331-6c3f4d4812d1">2022-12-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_20fc58f1-d309-49c4-8e36-1bf908e8002c">CANDEL THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_f0edec0d-127c-4532-aa0e-9da257a9146b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_25c5ac45-a99a-4271-846b-c9b1c4db0e9b">001-40629</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_f00976c1-9d79-41b7-8301-7f25230474da">52-2214851</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_d02ba6ea-9775-4cc5-a358-5bc8e17cb0f3">117 Kendrick St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_2289bd33-7cbd-432d-bbb8-903846bea75f">Suite 450</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_345a3e49-08f3-4c73-9ba4-b59cee65b4f0">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_e9c8aa16-c640-49e8-a6fb-bead3854c60e">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_2627a87b-b897-4b64-aced-8b22dede3239">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_a4be6d04-c1e2-4f51-a4dd-8b7645f8f28a">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_86a2e8e9-c974-46f7-9f7d-a28da55ca648">916-5445</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_97a8b751-6b04-4de0-ae08-bce7027bbb9b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_256d27b3-0155-43f2-8a64-93a2a314d2be">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_e577c49d-2532-49df-9c88-b721c09184a7">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_0de11d34-f3b5-41a9-bb7a-f93801704a7b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_0ac4b101-e471-4761-8c6f-68fd8a1a4e77">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_d655a468-7860-46e7-99b2-f7762fc22b55">CADL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_0265dbfc-8808-4830-b6dc-395f49d43e22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_6d1c12c6-09b0-4b18-99eb-967006ca9738">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_07573f72-2713-49f5-bb06-7e7b8e980e8d"
      id="F_84e36f53-d742-4581-92d7-162a01a42729">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MWOJ+PZW@4)SN!KB^5LJ^-]RK?_GE9O O4$L#!!0    ( ,F+AE6?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( ,F+AE4'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ R8N&5;.AGA+M    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ R8N&59E<G",0!@  G"<  !,
M         ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #)
MBX95\X7J:'X$  #%$0  &               @($,"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ R8N&59^@&_"Q @  X@P   T
M         ( !P P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #)BX95EXJ[
M',     3 @  "P              @ &<#P  7W)E;',O+G)E;'-02P$"% ,4
M    " #)BX95'#AEZC\!   \ @  #P              @ &%$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ R8N&520>FZ*M    ^ $  !H
M     ( !\1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ R8N&5660>9(9 0  SP,  !,              ( !UA(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cadl-20221206.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="cadl-20221206.htm">cadl-20221206.htm</File>
    <File>cadl-20221206.xsd</File>
    <File>cadl-20221206_lab.xml</File>
    <File>cadl-20221206_pre.xml</File>
    <File>cadl-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cadl-20221206.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "cadl-20221206.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cadl-20221206_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cadl-20221206_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cadl-20221206.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cadl",
   "nsuri": "http://www.candeltx.com/20221206",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cadl-20221206.htm",
      "contextRef": "C_07573f72-2713-49f5-bb06-7e7b8e980e8d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityAddressStateOrProvince",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "cadl-20221206.htm",
      "contextRef": "C_07573f72-2713-49f5-bb06-7e7b8e980e8d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityAddressStateOrProvince",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.candeltx.com/20221206/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-22-026104-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-026104-xbrl.zip
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MT:Z#-CS=.O@)[0\$Y? 7[1>RB,6!CW_?;Y<_U<VA**AF72S^&LOKSUO=-"F
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MNSU2V=$3&0NTK30$5TE:E<64B<YY]1*EJ]"?OUQ\03QE8Y6!6//G-C^@U=D
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M6!$;N8[4#V*AR+,-=%<6R#9VU@$.# 'NF_2M><).>18;;K%G+=A:FVS=O\>
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M2P$"% ,4    " #)BX95R\@$[CT4  !-]0  $0              @ $
M8V%D;"TR,#(R,3(P-BYH=&U02P$"% ,4    " #)BX95,./(SP@#  "?"0
M$0              @ %L%   8V%D;"TR,#(R,3(P-BYX<V102P$"% ,4
M" #)BX95E;>:QC<&  !V.0  %0              @ &C%P  8V%D;"TR,#(R
M,3(P-E]L86(N>&UL4$L! A0#%     @ R8N&53C%_%W(!   >BP  !4
M         ( !#1X  &-A9&PM,C R,C$R,#9?<')E+GAM;%!+ 0(4 Q0    (
M ,F+AE5> E^ -Q4  ,'A   /              "  0@C  !C861L+65X.3E?
;,2YH=&U02P4&      4 !0!! 0  ;#@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
